ArticleCancer science2013
CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma.
Article in Cancer science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.The American journal of tropical medicine and hygiene · 2018Pooled it
- The diagnostic performance of serum MUC5AC for cholangiocarcinoma: A systematic review and meta-analysis.Medicine · 2016Pooled it
- Emerging omics diagnosis of perihilar cholangiocarcinoma.Journal of gastroenterology · 2026Article
- Diagnostic value of carbohydrate antigen 50 in biliary tract cancer: A large-scale multicenter study.Cancer medicine · 2024Article
- Review
- Phosphorylated Proteins from Serum: A Promising Potential Diagnostic Biomarker of Cancer.International journal of molecular sciences · 2022Review
- A Novel Serum Glycobiomarker for Diagnosis and Prognosis of Cholangiocarcinoma Detected byMolecules (Basel, Switzerland) · 2021Article
- High expression of tissueThe Journal of international medical research · 2021Article
- Carbohydrate Antigen 50: Values for Diagnosis and Prognostic Prediction of Intrahepatic Cholangiocarcinoma.Medicina (Kaunas, Lithuania) · 2020Article
- Ganglioside GM2: a potential biomarker for cholangiocarcinoma.The Journal of international medical research · 2020Article
- Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway.Scientific reports · 2019Article
- Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view.Carcinogenesis · 2018Review
- Increased expression of the high-mannoseOncology letters · 2018Article
- Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma.Journal of translational medicine · 2016Article
- Differential Expression of O-glycoprotein Glycans in Cholangiocarcinoma Cell Lines.Asian Pacific journal of cancer prevention : APJCP · 2016Article
- Diagnostic and prognostic serum marker of cholangiocarcinoma (Review).Oncology letters · 2015Article
- An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.International journal of genomics · 2015Review
- Genetic and environmental determinants of risk for cholangiocarcinoma in Thailand.World journal of gastrointestinal pathophysiology · 2014Review
- Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.Journal of hepato-biliary-pancreatic sciences · 2014Review
- CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma.Cancer science · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early and specific diagnosis is critical for treatment of cholangiocarcinoma (CCA). In this study, a carbohydrate antigen-S27 (CA-S27) monoclonal antibody (mAb) was established using pooled CCA tissue-extract as immunogen. The epitope recognized by CA-S27-mAb was a new Lewis-a (Le(a)) associated modification of MUC5AC mucin. A Soybean agglutinin/CA-S27-mAb sandwich ELISA to determine CA-S27 in serum was successfully developed. High level of CA-S27 was detected in serum of CCA patients and could differentiate CCA patients from those of gastro-intestinal cancers, hepatomas, benign hepatobiliary diseases and healthy subjects with high sensitivity (87.5%) and high negative predictive value (90.4%). The level of serum CA-S27 was dramatically reduced after tumor removal, indicating tumor origin of CA-S27. Patients with high serum CA-S27 had significantly shorter survivals than those with low serum CA-S27 regardless of serum MUC5AC levels. Fucosyltransferase-III (FUT3) was shown to be a regulator of CA-S27 expression. Suppression of CA-S27 expression with siRNA-FUT3 or neutralization with CA-S27 mAb significantly reduced growth, adhesion, invasion and migration potentials of CCA cells in vitro. In summary, we demonstrate that serum CA-S27, a novel carbohydrate antigen, has potential as diagnostic and prognostic markers for CCA patients. CA-S27 involves in promoting cell growth, adhesion, migration and invasion of CCA cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.